Key Highlights

  • Intellia Therapeutics (NTLA) has 33.3% of its float sold short with 14.1 days to cover.
  • The FDA accepted the application for lonvo-z in hereditary angioedema (HAE) with priority review and a March 10, 2027 decision date.
  • Intellia secured a Debt Facility with $75 million funded upfront and $325 million tied to milestones; ARK Invest bought 204,000 shares.

Intellia Therapeutics (NASDAQ:NTLA) rose 1.1% to $12.29 in pre-market trading on above-normal volume, with 33.3% of its float sold short and 14.1 days to cover. The FDA has accepted Intellia's application for lonvo-z in hereditary angioedema with priority review and a March 10, 2027 decision date, a catalyst that could collide with one of biotech's most crowded short positions.

Intellia Therapeutics' short interest stands at 33.3 percent of the float, with 14 days needed to cover. Short sellers borrow and sell shares, betting on a decline; with 14 days needed to cover, a positive surprise could force them into a rush to buy, the classic short squeeze.

Intellia is a leader in CRISPR gene editing, and lonvo-z is designed as a one-time treatment for HAE, a rare genetic condition that causes dangerous swelling. An approval would make Intellia one of the first companies with an in-body CRISPR therapy on the market. The new debt facility helps fund the launch.

Intellia (NTLA) Rises With Biotech Peers

Absci rose 2.0%, Novavax 0.9% and Hemab was little changed, so both sector strength and company-specific factors drove the move. Dollar Volume was above normal. NTLA is up 32.0% year-to-date despite a decline over the past month, and the market Capitalization is about $1.7 billion. The 52-week range is $7.95 to $28.25.

NTLA Technical Levels

The 14-day RSI sits near the middle of its scale. RSI measures buying versus selling pressure on a 0 to 100 scale, and a neutral reading means the stock can move either way on news. For squeeze traders, a break above recent resistance on heavy volume is the signal to watch.

Financial Profile

Trailing-twelve-month Revenue was $59.51 million, largely from collaborations, with a 74.4% gross Margin but an Operating Margin of -711.7% and net margin of -672.2%. The stock trades at 27.7 times sales and 2.3 times book, with debt-to-equity of 0.10 and $106.13 million of cash and equivalents. Analysts rate NTLA a Buy with an average target near $24.

Peers Moving on This News